• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Charles Bowman & Company

  • Home
  • Company
  • Products
  • Exclusive Partners
  • News
  • Contact
You are here: Home / All News / New Maqui Extract Study Available

Filed Under: All News, CBC News, Industry News, Recent News Tagged With: Anklam Extrakt, Clinical, Maqui Berry, MNL Group

New Maqui Extract Study Available

Anklam Extrakt® continuously puts great emphasis on scientific research of their extracts, to prove the efficacy and to provide customers an added value.

At the end of 2018, our latest clinical study “Bioavailability Study of Maqui Berry Extract in Healthy Subjects” was published in the renowned peer-reviewed journal Nutrients.

The investigated product is an  extract from the Patagonian Maqui Berry exclusively produced by Anklam Extrakt® under GMP-compliance for MNL Group.

The extract is standardized to bear a minimum of 25% delphinidins and a minimum of 35% total anthocyanins. The efficacy of this anthocyanin-enriched extract has been investigated in other preclinical and clinical studies, showing effects in different health indications like tear fluid management, bone health and well-balanced blood sugar levels.

Bioavailability Study of Maqui Berry Extract

Within the course of the aforementioned study, the bioavailability of the standardized maqui berry extract was investigated based on two selected anthocyanins and two breakdown products (gallic acid and protocatechuic acid) after a single-dose supplementation in humans.
The results confirm a fast uptake and metabolism of the two selected key substances with significant increases in the plasma values of all 12 subjects (see figure).

 Download the Bioavailability Study 

February 21, 2019 By BowmanAdmin

Primary Sidebar

Categories

  • All News
  • CBC News
  • Industry News
  • Recent News
  • Trade Shows

Web design by OptimWise